Experimental Antiviral Therapeutic Studies for Human Rhinovirus Infections.

This effect did not reach statistical significance in all comers – ie, participants with no virus or non-picornavirus isolated – and more side effects were experienced overall in the pleconaril arm. 70 When submitted to the Food and Drug Administration (FDA) for approval in 2002 for the treatment of the common cold, it was declined as a number of other issues were identified with the results from the above studies and from prior phase II trials, including concerns about interference with the action of oral contraceptives and the lack of a significant reduction in symptoms in non-white participants.

also in 111,027 other papers